Sandoval ZJ

Language: Spanish
References: 13
Page: 69-75
PDF size: 94.74 Kb.

ABSTRACT

Pulmonary arterial hypertension is a progressive and lethal disease for which there is no effective cure. In recent years, however, there has been a significant progress in the knowledge about the pathobiologic mechanisms involved in the characteristic vascular damage of this disease. Knowledge has evolved from the importance of the vasoconstriction component originally contemplated to the current concept of a preponderant abnormal (fibromuscular) proliferation. This conceptual evolution has resulted in new and attractive pharmacologic interventions in an attempt to interrupt this abnormal process of vascular remodeling. In this review, the interventions derived from this pathobiologic knowledge are analyzed and based on the most recent controlled clinical trials; an evidence-based therapeutic strategy is established.

REFERENCES

1. SANDOVAL J, SEOANE M, BELTRÁN ME, ET AL: Circulación Pulmonar. En: Vargas-Barrón J (Ed) Texto de Cardiología, Sociedad Mexicana de Cardiología. Intersistemas, SA de CV., México D.F. 2006: 825-871.

2. RICH S: Classification and clinical features of pulmonary hypertension. In: Peacock A, and Rubin LJ (eds) Pulmonary Circulation 2nd Edition. Arnold. London 2004: 147-153.

3. SIMONNEAU G, GALIÉ N, RUBIN LJ, ET AL: Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S.

4. BARST RJ, MCGOON M, TORBICKI A, ET AL: Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 40S-47S.

5. FARBER HW, LOSCALZO J: Pulmonary arterial hypertension. Mechanisms of disease. N Engl J Med 2004; 351: 1655-65.

6. RUBIN LJ, BADESCH DB: Evaluation and management of the patient with pulmonary arterial hypertension. Ann Int Med 2005; 143: 282-292.

7. HUMBERT M, SITBON O, SIMONNEAU G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-36.

8. SIMONNEAU G, BARST RJ, GALIÉ N, ET AL : Continuous subcutaneous infusion of Treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 800-04.

9. RUBIN LJ, BADESCH DB, BARST RJ, ET AL: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.

10. BARST RJ, LANGLEBEN D, FROST A, ET AL : Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-47.

11. GALIE N, SEEGER W, NAEIJE R, ET AL: Comparative analysis of clinical trials and evidencebased treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 81S-88S.

12. GALIÉ N, GHOFRANI HA, TORBICKI A, ET AL: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-57.

13. SANDOVAL J, GASPAR J: Atrial Septostomy. In: Peacock A, and Rubin LJ (Eds) Pulmonary Circulation 2nd Edition. Arnold. London 2004: 319-333.